RXi Pharmaceuticals enters into research collaboration with Iovance Biotherapeutics

This article was originally published here

RXi Pharmaceuticals has partnered with Iovance Biotherapeutics to evaluate its sd-rxRNA therapeutic compounds with the latter’s autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply